Document is current
Any future updates will be listed below
-
Authors
Hatoyama, Yuki https://orcid.org/0000-0001-5554-8311
Islam, Moutushi https://orcid.org/0000-0002-0934-9247
Bond, Adam G https://orcid.org/0000-0002-1271-1032
Hayashi, Ken-ichiro
Ciulli, Alessio https://orcid.org/0000-0002-8654-1670
Kanemaki, Masato T https://orcid.org/0000-0002-7657-1649
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science London (JP21H04719)
Japan Society for the Promotion of Science London (JP23H04925)
Japan Society for the Promotion of Science London (JSPS Research Fellow for Young Scientists (DC2) (JP23KJ0999))
MEXT | JST | Core Research for Evolutional Science and Technology (JPMJCR21E6)
Ministry of Education, Culture, Sports, Science and Technology (MEXT scholarship ID 203193)
- License Information
-
More Information
Article History
Received: 6 March 2024
Revised: 23 July 2024
Accepted: 24 July 2024
First Online: 23 August 2024
Disclosure and competing interests statement
: AC is a scientific founder, shareholder, and advisor of Amphista Therapeutics, a company that is developing targeted protein degradation therapeutic platforms. The Ciulli laboratory receives or has received sponsored research support from Almirall, Amgen, Amphista Therapeutics, Boehringer Ingelheim, Eisai, Merck KaaG, Nurix Therapeutics, Ono Pharmaceutical, and Tocris-Biotechne. The remaining authors declare no competing interests.
